Stockwinners Market Radar for November 22, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:29 EST Former SEC lawyer Misler joins Tesla as managing counsel - Former SEC trial unit lawyer David Misler said in a post on his LinkedIn profile that he is joining Tesla as managing counsel for litigation. "Today, a new journey begins," Misler said. "I start at #Tesla as a managing counsel for litigation where I will support our important mission of accelerating the world's transition to sustainable energy. I am excited to join such an innovative and disruptive company and am ready for the opportunities and challenges ahead." Reference Link

19:01 EST South Jersey Industries raises quarterly dividend 2.48% to 31c per share - SJI announced that its board of directors voted to increase the company's regular quarterly dividend from 30.25c per share to 31c per share. The new annualized dividend of $1.24 represents an increase of 2.48% per share over the previous level. With this announcement, SJI has increased its dividend for 23 consecutive years, the company said.

18:25 EST Lee Enterprises confirms $24.00 per share buyout proposal from Alden Global - Lee Enterprises confirmed that it has received an unsolicited non-binding proposal from Alden Global Capital to purchase Lee Enterprises for $24.00 per share in cash. "Lee's Board of Directors and management team are committed to acting in the best interests of all shareholders. Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Lee's Board of Directors will carefully review Alden's proposal to determine the course of action that it believes is in the best interests of the company and Lee shareholders. There is no need for Lee shareholders to take any action at this time."

18:14 EST Lee Enterprises confirms $24.00 per share buy out proposal from Alden Global - Lee Enterprises confirmed that it has received an unsolicited non-binding proposal from Alden Global Capital to purchase Lee Enterprises for $24.00 per share in cash. "Lee's Board of Directors and management team are committed to acting in the best interests of all shareholders. Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Lee's Board of Directors will carefully review Alden's proposal to determine the course of action that it believes is in the best interests of the company and Lee shareholders. There is no need for Lee shareholders to take any action at this time."

17:21 EST Lockheed Martin awarded $114.61M Navy contract command - Lockheed Martin was awarded an $114.61M cost-plus-incentive-fee, cost-plus-fixed-fee, and cost-only modification to a previously-awarded contract to exercise an option for AEGIS Combat System Engineering Agent efforts for the design, development, integration, test and delivery of Advanced Capability Build 20. Work will be performed in Moorestown, New Jersey, and is expected to be completed by December 2022. FY21 other procurement funds in the amount of $430,000 and FY22 research, development, test, and evaluation funds in the amount of $382,216 will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:19 EST Emergent BioSolutions to replace Domtar in S&P 600 at open on 11/30 - Paper Excellence B.V. is acquiring Domtar in a deal expected to be completed soon pending final conditions.

17:15 EST Pfizer awarded $1.4B Army contract modification for 200M COVID-19 vaccine doses - Pfizer was awarded a $1.4B modification to a contract for an additional 200M doses of Pfizer's COVID-19 vaccine for international donation. Work will be performed in New York, New York, with an estimated completion date of June 30, 2022. FY22 research, development, test, and evaluation, Army funds in the amount of $1.4B were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:05 EST Hormel Foods raises annual dividend 6% to $1.04 from 98c per share - The Board of Directors authorized the first quarterly dividend of 26c a share to be paid on Feb. 15, 2022, to stockholders of record at the close of business on Jan. 18, 2022.

16:37 EST Urban Outfitters drops 11% to $33.05 after reporting Q3 results

16:32 EST GCP Applied Technologies implements price increases for Concrete Admixtures - GCP Applied Technologies announced it is implementing price increases for Concrete Admixtures in North America. To continue providing the exceptional solutions GCP's customers rely on, at the levels of service they require, it is necessary to increase prices up to 10% for all concrete admixture and fiber products effective January 1, 2022.

16:31 EST Installed Building Products acquires CFI Insulation, terms undisclosed - Installed Building Products announced the acquisition of CFI Insulation. Established in 2003, CFI is headquartered in Knoxville, Tennessee and primarily installs fiberglass and spray foam insulation into new residential, multifamily and commercial construction projects. "With approximately $10 million of annual revenue, CFI expands our presence to residential, multifamily and commercial customers throughout Tennessee," stated Jeff Edwards, chairman and CEO. "To date in 2021, we have acquired approximately $140 million of annual revenues, further surpassing our $100 million acquired revenue target for this year. Acquisitions remain a key component of our growth strategy and we continue to have a robust pipeline of opportunities across multiple geographies, products, and end markets. On behalf of everyone at Installed Building Products, I would like to welcome CFI onto our team."

16:25 EST Zoom Video sees Q4 deferred revenue growth in the mid 20s y/y - Says deferred revenue growth to be driven by the cyclical decline in the average remaining term of the company's annual customer contracts, which are front-half weighted. Says deferred revenue at end of Q3 was $1.2B, slightly up quarter over quarter. Comments taken from Q4 earnings call prepared remarks.

16:22 EST Array Technologies announces CEO Jim Fusaro to retire ~December 31, 2022 - Array Technologies announced that Jim Fusaro, Chief Executive Officer, has informed the board of his intent to retire from the company on or before December 31, 2022. The Board of Directors is engaged in a search to identify Mr. Fusaro's successor. "

16:20 EST AvalonBay names Benjamin Schall CEO, Timothy Naughton executive chairman - AvalonBay Communities announced that Benjamin W. Schall, the Company's current President and a director, has been appointed to the additional role of Chief Executive Officer effective January 3, 2022, reporting directly to the Board. Concurrently, Timothy J. Naughton, the Company's current Chairman of the Board and Chief Executive Officer, will retire as the Company's Chief Executive Officer and assume the role of Executive Chairman of the Board. These appointments are consistent with the expectations previously announced by the Company in December 2020 as part of its leadership succession plan. "During the past year, Ben has proven to be a wonderful steward of AvalonBay's culture, meaningfully connecting with AvalonBay's associates across the organization, in our regions and at our communities. He shares our organizational values, our vision of success, and our commitment to creating an inclusive and diverse workplace," said Mr. Naughton. "Since joining AvalonBay in January 2021, Ben has become integrally involved across the organization and, externally, has established relationships with many of our key stakeholders and shareholders. As we continue to grow, execute and innovate, Ben and the executive team are well positioned to lead the Company forward."

16:18 EST UFP Industries acquires controlling equity position in Ficus Pax for $13.5M - UFP Industries announced that its affiliate, UFP Global Holdings, has acquired 70% of the equity in Ficus Pax, a producer of industrial packaging in India, for approximately $13.5M. Headquartered in Bangalore, India, Ficus Pax manufactures mixed-material cases and crates, nail-less plywood boxes, wooden pallets and other packaging products through 10 facilities located in industrial markets throughout southern India. Ficus Pax also owns a majority stake in Wadpack, a manufacturer of corrugated fiber board containers, corrugated pallets and display solutions. The company had trailing 12-month sales through August of approximately $39M. Sandeep Wadhwa, chairman and managing director of Wadpack, will now lead Ficus Pax as managing director over the consolidated group.

16:08 EST Keysight Technologies authorizes up to $1.2B share buyback program - Keysight announced that its Board of Directors authorized a new share repurchase program for up to $1.2 billion of its common stock. The new repurchase program is effective immediately and replaces the previously authorized $750 million program from 2020 of which $77 million remained. Shares may be purchased from time to time, subject to general business and market conditions and other investment opportunities, through open market purchases, privately negotiated transactions or other means. The repurchase authorization may be commenced, suspended or discontinued at any time at the company's discretion.

16:04 EST WillScot Mobile Mini acquires regional storage services assets in LA, no terms - WillScot Mobile Mini Holdings announced that it closed the acquisition of the assets of Portable Storage Corporation in Los Angeles. The transaction was funded with cash on hand and borrowings under the Company's revolving credit agreement. This acquisition adds about 3,000 storage units in the Company's existing U.S. markets in California. Brad Soultz, Chief Executive Officer, commented, "I am excited to welcome the employees of Portable Storage Corporation to our team at WillScot Mobile Mini. Portable Storage Corporation's operations expand our presence and capabilities in the greater Los Angeles area. Consistent with our M&A strategy, we look forward to providing our 'Ready to Work' value proposition to new customers, and applying our commercial and organizational best practices, while leveraging our scalable technology platform. Thank you to both our new and existing team members who are now working together to integrate our operations in southern California."

16:01 EST Roche's obinutuzumab granted FDA orphan designation - Genentech, a unit of Roche, was granted orphan designation from the FDA for obinutuzumab for the treatment of childhood-onset idiopathic nephrotic syndrome, or NS, defined as steroid dependent or frequently relapsing NS, according to a post to the agency's website. Reference Link

15:50 EST Canadian Pacific to reopen B.C. rail corridor Tuesday - Canadian Pacific announced that it would reopen its railway between Kamloops, B.C. and Vancouver by mid-day Tuesday, Nov. 23. "Crews have worked around the clock after the Nov. 14 atmospheric river rain storm in British Columbia, where nearly 200 millimetres of rain fell over two days in some locations. Thirty locations across CP's Thompson and Cascade subdivisions were damaged with 20 resulting in significant loss of infrastructure... As CP resumes operations and moves from restoration to recovery, CP will closely coordinate with customers and terminals to clear the backlogs as quickly and efficiently as possible. Success will require collaboration across the supply chain with urgent weekend work and flexible schedules at customer and terminal locations to help get freight moving efficiently again," the company stated.

15:16 EST Twitter introduces ' aliases' for participants in its Birdwatch moderation tool - Twitter blogged, in part, earlier, that its croud-sourced tweet moderation tool, Birdwatch, is incorporating aliases for participants in its moderation tool: "We want everyone to feel comfortable contributing to Birdwatch. Aliases let contributors write and rate notes without sharing their Twitter usernames. A Birdwatch alias is a new, auto-generated display name that participants get when they join Birdwatch. Aliases are not publicly associated with contributors' Twitter accounts, so everyone can write and rate notes privately. Further, we believe aliases have the potential to: Reduce bias. By keeping focus on the content of notes rather than who's writing them, aliases have the potential to reduce bias that people might have around specific authors. Reduce polarization. Recent research indicates aliases might reduce polarization by helping people feel comfortable crossing partisan lines, or criticizing their own side without the prospect of peer pressure or retribution." Reference Link

14:56 EST Sorrento executes contract for sale of 5M COVI-STIX tests for Mexican market - Sorrento Therapeutics announced its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with "a leading local distributor" for the sale and distribution of up to 5M COVI-STIX tests for the Mexican market. "Since its commercial launch in July, the COVI-STIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results. In addition, independent clinical testing by a leading Mexican national institute demonstrated very high sensitivity of around 90% when tested for all-comers, including asymptomatic COVID-19 virus carriers, while most of the other rapid COVID-19 virus antigen tests evaluated failed to achieve sensitivity above 62%," Sorrento said.

13:48 EST Portnoy says Barstool Sportsbook now live in West Virginia - Barstool founder Dave Portnoy tweeted: "Barstool Sportsbook Now Live in West Virginia". Penn Interactive (PENN) currently operates online Barstool Sportsbooks across several U.S. states. Reference Link

13:19 EST Happiness Biotech reaches cooperation with Shanghai Autmobile - Happiness Development Group announced that its automobile sales brand, Taochejun's subsidiary, has reached a sales agreement with Shanghai Automobile Trading, a wholly owned subsidiary of Shanghai Automobile Industry Corporation, to purchase 1,300 vehicles from the SAIC MG brand at a discounted price. According to the agreement, Taochejun's subsidiary, Happiness Automobile Services, will purchase 1300 "MG HS", with a total consideration of approximately RMB104M from Shanghai Automobile Trading. These vehicles will be sold at a 37% discount compared with their official guide price.

13:05 EST Netflix announces plans to acquire Scanline VFX, terms not disclosed - Netflix announced plans to acquire Scanline VFX, a company known for its "complex, photorealistic effects and expertise in virtual production." Netflix will "invest in Scanline's pipeline, infrastructure and workforce and continue to support the pioneering work that Scanline's Eyeline Studios is doing in virtual production to push the boundaries of what is visibly possible," the company said in a statement. It added, "We'll also continue to rely on many other studios around the world for our VFX needs so we can continue to ensure that our creators have access to the world's most innovative tech, and continue to bring the most compelling and cutting-edge storytelling to our members." Reference Link

12:34 EST Pentwater says Turquoise Hill director breached fiduciary duty - Pentwater Capital Management, the largest minority shareholder of Turquoise Hill Resources, sent a letter to the company's director George Burns. Burns "has not responded to explain his role in the ongoing and likely future breaches of fiduciary duties by the Turquoise Hill Board towards its minority shareholders," Pentwater said in a statement. The letter from Pentwater Capital Management CEO Matthew Halbower to Burns stated in part, "I am writing to you to implore you to not breach your fiduciary duty owed to minority shareholders of Turquoise Hill. Unfortunately, I believe that you have already done so, and if press reports are accurate, I believe you are about to further breach your fiduciary responsibilities in one of the most egregious ways that I have ever seen in my career. As you know, you joined the Board of TRQ six months after TRQ announced a $1.5 billion cost overrun and a two-year delay in the construction of the Oyu Tolgoi underground mine. At that time, I sincerely hope you were not aware that it was Rio's concealed mismanagement that caused the cost overrun and schedule delay...We implore you to use your voice to not allow Rio to run roughshod over the rights of TRQ minority shareholders."

12:09 EST Walmart to be first retailer to test Twitter's livestream shopping platform - Twitter (TWTR) said in a thread: "Today we announced our latest Twitter Shopping experiment: Live Shopping! Whether you're a home shopping super fan or catching up on your favorite creator's latest purchases, live video has been transforming the way we shop for years. We are incredibly excited to be partnering with one of the most recognizable brands in the world, @Walmart (WMT) for this test! Be sure to tune into their Live Event, hosted by @jasonderulo on November 28 at 7pm ET! Live Shopping on Twitter gives businesses the power to engage with their most influential fans, in a space where they are most receptive. But we know there is more for us to explore and iterate on. Stay tuned for more and in the meantime, be sure to chat, watch, and SHOP!" Reference Link

12:00 EST IonQ falls -17.8% - IonQ is down -17.8%, or -$4.98 to $23.03.

12:00 EST Avaya rises 19.3% - Avaya is up 19.3%, or $3.48 to $21.45.

12:00 EST MultiPlan rises 26.1% - MultiPlan is up 26.1%, or 92c to $4.44.

11:54 EST Fiserv completes acquisition of BentoBox - Fiserv announced the completion of its acquisition of BentoBox. "Closing this transaction further expands our Clover(R)dining solutions and industry-leading commerce and business management capabilities, enabling nearly 200,000 restaurants of all sizes to deliver unique and differentiating diner experiences, from quick and casual to full service," said Frank Bisignano, President and CEO of Fiserv.

11:02 EST Oscar Health, Emory Healthcare collaborate to offer health insurance, care - Oscar Health and Emory Healthcare announced a collaboration to offer technology-connected health insurance and care at more than 250 provider locations in Georgia beginning 2022. This new collaboration brings an additional insurance coverage option to Georgians seeking care at Emory Healthcare in metro Atlanta and Columbus, Georgia. The companies said, "Through the Oscar and Emory Healthcare initiative, more Georgia consumers have access to individual and family health insurance plans, focused on innovation and ease. The clinical and insurance experience will be driven by the combination of Emory Healthcare's leading network of providers via the Emory Healthcare Network's clinically integrated offering and Oscar's consumer-centric, technology-driven, innovative approach to customer service and care navigation."

11:01 EST Raven awarded prime contract for stratospheric balloon systems & services - Raven Industries announced that Defense Innovation Unit has awarded a contract to Aerostar Technical Solutions to provide robust high-altitude capabilities for the U.S. Department of Defense. DIU is focused on exclusively fielding and scaling commercial technology for use across the U.S. military. Through a variety of service-driven prototyping and field utility demonstration efforts, Raven Aerostar will demonstrate the utility of stratospheric balloons for a variety of DoD operational needs. The prototype project will begin with the integration of prototype communication nodes onto Raven Aerostar's Thunderhead Balloon Systems to demonstrate connectivity to the warfighter at the edge. Additional flight tests will provide integrated payloads for airborne data collection. Through this project, DIU will evaluate Raven Aerostar's stratospheric technology for transition to live military field operations.

10:38 EST Humana announces value-based agreement with Allina Health in Minnesota - Humana and Allina Health announced they are expanding their existing agreement to focus on value-based care for Humana's Medicare Advantage members in Minnesota. "This multi-year agreement, which takes effect Jan. 1, 2022, is in keeping with Humana's long-standing commitment to value-based care," the company stated. Chuck Dow, VP, Humana's Medicare Regional President for Minnesota, added: "We're excited to share with Allina Health a strong commitment to providing quality care while improving patient health outcomes in Minnesota."

10:27 EST Alden Global Capital offers to acquire Lee Enterprises for $24.00 per share - Alden Global Capital sent the following letter to the Board of Directors of Lee Enterprises: "Alden Global Capital is a significant investor in American newspapers, with platforms including MediaNews Group, Inc. and Tribune Publishing Company that are committed to ensuring communities nationwide have access to robust, independently minded local journalism. Our goal is to provide valued news and information to local subscribers nationwide, led by a talented team of seasoned newspaper executives who have worked in journalism for an average of more than 30 years. Our newspapers include The Chicago Tribune, The Denver Post, The Mercury News, The New York Daily News, The Orange County Register, The Boston Herald, The Baltimore Sun and other leading newspapers across the U.S. As you are aware, an affiliated entity of ours owns approximately 6% of the issued and outstanding common stock of Lee Enterprises, Incorporated. We believe that as a private company and part of our successful nationwide platforms, Lee would be in a stronger position to maximize its resources and realize strategic value that enhances its operations and supports its employees in their important work serving local communities. Our interest in Lee is a reaffirmation of our substantial commitment to the newspaper industry and our desire to support local newspapers over the long term. Accordingly, we propose to purchase Lee for $24.00 per share in cash, representing a substantial premium of approximately 30% to Lee's closing share price of $18.49 on November 19th, 2021. We have the ability to fully finance this all-cash proposal and the definitive merger agreement will not include a financing condition. We have engaged an experienced team of advisors, including Moelis & Company as financial advisor as well as Akin Gump Strauss Hauer & Feld LLP and Olshan Frome Wolosky LLP as legal counsel, and have conducted a comprehensive review of publicly available information about Lee. Based on our review of this information and in consultation with our counsel, we do not believe any material regulatory issues would inhibit the completion of this transaction in a timely manner. The foregoing indicative terms are based solely on our review of publicly available information, are subject to completion of our due diligence and execution of definitive documentation acceptable to us and we reserve the right to withdraw or modify our proposal in any manner. Following the review of targeted additional information pursuant to a mutually acceptable nondisclosure agreement, we expect that we would complete our work, including negotiation of definitive documentation, in approximately four weeks. We are keenly interested in working constructively with the Lee Board of Directors, with the goal of getting to a successful transaction with value, speed and certainty. Scale is critical for newspapers to ensure necessary staffing and in order to thrive in this challenging environment where print advertising continues to decline and back office operations and legacy public company functions remain bloated, thus depriving newsrooms of resources that are best used serving readers with relevant, trustworthy and engaging content. We hope that the Board will work with us to maximize value and opportunities for all Lee stockholders and employees, and we look forward to receiving a response to this non-binding proposal in an expeditious manner."

10:04 EST Penn National set to open Hollywood Casino Morgantown on December 22 - Penn National Gaming announced that it expects to open Hollywood Casino Morgantown to the public on Wednesday, December 22nd, at Noon, pending final regulatory approvals. Hollywood Casino Morgantown is conveniently located at the intersections of three major roadways: the Pennsylvania Turnpike, I-176, and the Morgantown Expressway. The Morgantown Category 4 casino represents Penn National's fourth facility in Pennsylvania, joining Hollywood Casino at Penn National Race Course in Grantville, Hollywood Casino at the Meadows in Washington and Hollywood Casino York, which opened in August.

10:00 EST DigitalOcean falls -10.1% - DigitalOcean is down -10.1%, or -$12.97 to $115.56.

10:00 EST Avaya rises 12.7% - Avaya is up 12.7%, or $2.29 to $20.27.

10:00 EST Itau Corpbanca rises 14.2% - Itau Corpbanca is up 14.2%, or 43c to $3.45.

09:47 EST DigitalOcean falls -8.1% - DigitalOcean is down -8.1%, or -$10.36 to $118.17.

09:47 EST Enel Americas rises 11.5% - Enel Americas is up 11.5%, or 65c to $6.30.

09:47 EST Nacco Industries rises 13.8% - Nacco Industries is up 13.8%, or $4.24 to $34.87.

09:42 EST Aurinia sinks with buyout speculation seen as 'past its expiration' - Shares of Aurinia Pharmaceuticals are falling after the company late Friday filed a prospectus agreement to sell shares. Aurinia also entered a sales agreement, which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250M of common shares that may be issued and sold from time to time under a controlled equity offering sales agreement with Cantor Fitzgerald. Following the news, STAT's Adam Feuerstein tweeted that Aurinia's "buyout speculation looks well past its expiration date." Aurinia Pharmaceuticals shares are down 18% to $23.25 in early trading.

09:34 EST GoDaddy announces security incident affecting up to 1.2M WordPress customers - In a blog post and regulatory filing, GoDaddy stated: "On November 17, 2021, we discovered unauthorized third-party access to our Managed WordPress hosting environment. Here is the background on what happened and the steps we took, and are taking, in response: We identified suspicious activity in our Managed WordPress hosting environment and immediately began an investigation with the help of an IT forensics firm and contacted law enforcement. Using a compromised password, an unauthorized third party accessed the provisioning system in our legacy code base for Managed WordPress. Upon identifying this incident, we immediately blocked the unauthorized third party from our system. Our investigation is ongoing, but we have determined that, beginning on September 6, 2021, the unauthorized third party used the vulnerability to gain access to the following customer information: Up to 1.2 million active and inactive Managed WordPress customers had their email address and customer number exposed. The exposure of email addresses presents risk of phishing attacks; The original WordPress Admin password that was set at the time of provisioning was exposed. If those credentials were still in use, we reset those passwords; For active customers, sFTP and database usernames and passwords were exposed. We reset both passwords; For a subset of active customers, the SSL private key was exposed. We are in the process of issuing and installing new certificates for those customers. Our investigation is ongoing and we are contacting all impacted customers directly with specific details... We are sincerely sorry for this incident and the concern it causes for our customers. We, GoDaddy leadership and employees, take our responsibility to protect our customers' data very seriously and never want to let them down. We will learn from this incident and are already taking steps to strengthen our provisioning system with additional layers of protection."

09:28 EST Lixte Biotechnology says enrollment resumes in NCI trial of LB-100 - Lixte Biotechnology Holdings announced that the National Cancer Institute has resumed enrolling patients into their pharmacologic study of the ability of Lixte's lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. After enrolling two patients in the study, enrollment was suspended in 2020 due to COVID-19 restrictions. Those restrictions have now been lifted and patient recruitment has resumed. Up to 20 patients may be enrolled to obtain 8 evaluable subjects. A two-stage design will be used. Five patients will be initially treated. If at least 1 of 5 demonstrates the presence of LB-100 in tumor tissue, 3 additional subjects will be enrolled. If at least 2 of the 8 patients demonstrate LB-100 in tumor tissue, the study will be considered significant providing further support for studying if the addition of LB-100 to standard treatment regimens for malignant brain tumors improves outcomes. This study is being conducted by the National Cancer Institute under a Cooperative Research and Development Agreement with Lixte.

09:21 EST XFuels renegotiates convertible debenture - On October 12th, 2021, Xfuels announced that CEO Mike McLaren has elected to convert his convertible promissory note of $1.3M into 125M shares of restricted common stock. After further consideration, Mr. McLaren has since elected to rescind that decision and renegotiate the convertible note to a fixed interested bearing secured instrument without a conversion option. This renegotiation of the note will still eliminate $1,468,638 of derivative liability from Xfuels' balance sheet.

09:20 EST Capital Power to highlight decarbonization focus at Investor Day - Capital Power Corporation will host its 13th annual Investor Day event virtually on December 2, 2021. Members of the executive leadership team will present on various topics including execution of the company's strategy, maximizing asset value in operations, growth opportunities and market outlook, environmental, social, governance initiatives, and 2022 corporate and financial targets.

09:17 EST Matterport announces completion of SOC 2 Type II Audit - Matterport announced it has successfully completed a SOC 2 Type II Service Organization Control audit for its platform and services. Performed by independent Certified Public Accountant firm, Frank, Rimerman + Co. LLP, the audit provides an objective evaluation of the effectiveness of controls involving operations and compliance at Matterport. Created by the American Institute of Certified Public Accountants, SOC2 is a reporting framework that sets benchmarks for managing customer data. The completion of the SOC 2 Type II audit attests Matterport's commitments to maintaining proper security, availability, and operational controls are in place for managing its spatial data platform and services.

09:11 EST Aditx Therapeutics announces 1st national agency to deploy AditxtScore - Aditxt announced that the Johnson County Sherriff's Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore for assessing the immune status for COVID-19 in its employees. AditxtScore is an immune monitoring platform which provides a personalized and comprehensive profile of the immune system. AditxtScore for COVID-19 helps to answer the growing need for a personalized approach to combating the pandemic. AditxtScore further differentiates itself by quantitatively measuring the strength of an individual's immune response to the novel coronavirus with high precision, helping patients and their providers make informed decisions for a proper course of action. Sheriff Calvin Hayden commented, "If an individual's antibodies are low, they may decide to get the vaccine or a booster. Alternatively, if their antibodies are high, either due to natural infection or from the vaccine, it may be best for them to wait on the booster. With their AditxtScore , they will finally have the information to guide these important health decisions - information they do not currently have. Informed individuals are empowered to make healthy decisions." He added, "The Johnson County Sheriff's Office has done a stellar job of managing COVID-19. We haven't skipped a beat in the services we've provided, and the AditxtScore( immune profile takes it to the next level." "AditxtScore provides meaningful information to help understand one's personal immune response to COVID-19 and not just that of the population collectively," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. Aditxt's immune monitoring platform is a pioneering approach to the health of our immune system. "

09:09 EST WWE, Special Olympics expand global partnership - Special Olympics and WWE announced a multi-year extension of their global partnership to help create inclusion through sports. WWE will continue to support Special Olympics Unified Sports, which brings together people with and without intellectual disabilities on the same team. It was inspired by a simple principle: training together and playing together is a quick path to friendship and understanding. WWE Superstars will continue to engage with Special Olympics athletes all around the globe through Unified Sports. Over the past few years, WWE Superstars have participated in Unified soccer in Italy, Unified flag football in Arizona, Unified bocce in Las Vegas, Unified soccer in UAE along with several other events, panels, and leadership conferences. Superstars have also reached out to Special Olympics athletes to encourage them in training and to congratulate them for achievements.

09:08 EST U.S. Army names BAE Systems prime on $2.4B cyber security support contract - The U.S. Army has selected BAE Systems to serve as a prime contractor on Lot 1 of the 10-year, $2.4B National Cyber Range Complex Event Planning, Operations, and Support hybrid contract. Under this indefinite delivery, indefinite quantity multiple award contract, the company will compete for orders in cybersecurity integration, range support services, systems testing, and training personnel. We look forward to harnessing our digital engineering expertise in integration and testing holistic cyber range environments, as well as training warfighters to operate in highly complex, challenging environments," said Lisa Hand, vice president and general manager of BAE Systems' Integrated Defense Solutions business. "Our experience in weapon systems, cyber-hardening, cybersecurity, and risk mitigation applications will better prepare warfighters for the future battlefield."

09:06 EST Norwegian Cruise Line completes balance sheet optimization transactions - Norwegian Cruise Line announced that it has closed on a series of related balance sheet and cash flow optimization transactions initiated last week. The net result of these strategic transactions is "significantly favorable for the Company and its shareholders as it reduces annual interest expense, lowers leverage, extends the Company's debt maturity profile and increases its liquidity," the company said. A benefit of these related transactions is that assuming the newly issued 1.125% exchangeable senior notes due 2027 are settled entirely in cash, at the Company's election, the Company will benefit from a net reduction in its diluted shares outstanding of approximately 5.2M shares. "The completion of these balance sheet and cash flow optimization transactions represents an important milestone for our Company as we have now taken the first significant step forward in executing on our post-crisis financial recovery plan," said Mark Kempa, Executive Vice President and Chief Financial Officer of Norwegian Cruise Line Holdings Ltd. "We are focused on maximizing value for all of our key stakeholders and we believe this transaction delivers long-term benefits from multiple perspectives by reducing our annual interest expense, reducing our outstanding debt, extending our debt maturities and increasing liquidity, all while providing additional flexibility to limit future shareholder dilution. While our ability to clearly and fully communicate the significant and expected multiple benefits of these transactions to our valued shareholders was limited by contractual and legal restrictions prior to completion of these transactions, we are pleased to now be able to convey the highlights of the transactions to our various stakeholders."

09:05 EST Nokia upgrades Guadalajara 5G lab to test new use cases - Nokia announced that it has upgraded its 5G testing lab located in Guadalajara, Mexico to support testing across new uses cases. The facility will enable the testing of new 5G products, as well as support growing sales and supply chain operations in the region. Nokia's Guadalajara Lab began operations in 2017 and develops and executes a wide range of tests for Nokia hardware solutions, such as radio frequency testing for 3G, 4G and 5G networks. It also includes additional testing for product change notification, chamber thermal testing, mechanical analysis, mechanical first article inspection, mechanical testing, digital data analysis and power supply analysis and realistic performance monitoring. Having received significant investment over the past five years, the lab works closely with Nokia's design facilities in Dallas, Texas and Naperville, Illinois, USA.

09:05 EST Uber Canada, Tokyo Smoke announce exclusive partnership - Tokyo Smoke, a cannabis retailer, and Uber Canada have announced an exclusive partnership to provide a new way to order cannabis in Ontario. Beginning immediately, Uber Eats has created a dedicated section on its digital marketplace for Tokyo Smoke's virtual stores. Consumers can place orders from Tokyo Smoke's flower collection and unique accessories on the Uber Eats app, and then pick up their purchase at the respective Tokyo Smoke stores. This is an innovative arrangement between Uber Eats and Tokyo Smoke, which is the first cannabis merchant to list itself using the Uber Eats software, across Uber's global business. Online ordering and pickup using Uber Eats is an innovative, new way for Canadian adults to conveniently and safely purchase legal cannabis. All orders will be fulfilled within an hour of the order being placed, so consumers are able to receive their items quickly.

09:03 EST Lantern Pharma approves $7M share repurchase program - Lantern Pharma announced that its board of directors has authorized a share repurchase program to acquire up to $7M of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the SEC and other applicable legal requirements. As of September 30 the Company had approximately $73.8M of cash, cash equivalents and marketable securities. The Company had approximately 11.2M shares of common stock outstanding as of October 29.

09:02 EST Great Lakes Dredge receives $92.5M dredging contract - Great Lakes Dredge & Dock Corporation announced the signing of a $92.5M dredging contract for the Houston Ship Channel Widening and Improvement Project 11. This is the first phase of the extensive, multi-phase Houston Ship Channel billion-dollar expansion and deepening program. Dredging is expected to commence in the first quarter of 2022 with estimated completion in the fourth quarter of 2022.

09:01 EST Aviat Networks approves $10M stock repurchase program - Aviat Networks announced that its Board of Directors has authorized a stock repurchase program. Under the program, Aviat Networks may purchase up to $10M of its outstanding common stock. This program is in addition to our previous $7.5M stock buyback program for which funds have been exhausted. The Company may choose to suspend or discontinue the repurchase program at any time. The repurchase program does not obligate the Company to purchase any number of shares.

08:58 EST Auxly Cannabis acquires 100% ownership of Sunens Farms - Auxly Cannabis Group announced that it has acquired 100% ownership of Sunens Farms. Pursuant to a share purchase agreement between Auxly and Peter Quiring, the Company acquired all the issued and outstanding securities of Sunens not already owned by Auxly. Concurrent with the Acquisition, Sunens and the Company have amended and restated Sunens' secured credit facility that was entered into in September 2019 underwritten by a syndicate of lenders led by the Bank of Montreal, bringing the total principal indebtedness thereunder to $62.5M. Auxly acquired all of the issued and outstanding securities of Sunens not already owned by Auxly from Peter Quiring for consideration of: $1.6M comprised of $500,000 in cash and $1.1M in Auxly common shares; a $3.4M unsecured promissory note payable over 30 months in equal monthly installments with the first payment due 12 months after the date of closing; and the transfer of certain non-core assets of Sunens. Concurrent with the Acquisition, Sunens has entered into an Amended and Restated Credit Facility with the following terms: An immediate cash payment by Auxly of $15M applied to the outstanding principal balance of the revolving credit facility, bringing the outstanding principal amount thereunder to $62.5M; Extension of the maturity date by a year to September 30, 2023, with an option for Sunens to extend for an additional year by making a further principal repayment of $5M by December 31, 2022; and The obligations of Sunens under the Amended and Restated Credit Facility continue to be supported by an unsecured $33M limited recourse guarantee by Auxly, and a pledge by the Company of all of its securities of Sunens with new revenue and EBITDA covenants. The Company will immediately begin integrating Sunens' proven cultivation capabilities, giving Auxly the competitive advantages of scale, lower costs and surety of supply as it continues to build to leadership in 1.0 cannabis product formats following on the success of its Back Forty branded flower and pre-rolls product launches. The Acquisition will result in improvements in Auxly's blended gross margins, adjusted EBITDA and net income as Sunens continues to increase production while eliminating the reliance on Auxly's third-party cannabis purchases. The facility is fully licensed for cultivation, processing and sales under the Cannabis Act and provides the Company with operational flexibility as well as considerable additional cultivation, storage, processing and manufacturing capacity and the ability to continue scaling cultivation to meet the growing consumer demand for Auxly's branded products. The transaction provides the Company with complete control over large-scale cultivation with a proprietary genetic library consisting of more than 150 cannabis strains, empowering Auxly to tailor its products to evolving consumer preferences and support the Company's growing portfolio in both the 1.0 and 2.0 cannabis product categories.

08:51 EST Ballard Power announces collaboration project with Caterpillar and Microsoft - Ballard Power Systems (BLDP) announced that the company has launched a three-year project through a collaboration with Caterpillar (CAT) and Microsoft (MSFT) to demonstrate a power system incorporating large-format hydrogen fuel cells to produce reliable and sustainable backup power for data centers. The project is supported and partially funded by the U.S. Department of Energy, or DOE, under the H2@Scale initiative and backed by the National Renewable Energy Lab, or NREL. Ballard will provide an advanced, 1.5 MW ClearGenTM-II hydrogen fuel cell power generator.

08:47 EST Ballard Power announces collaoration project with Caterpillar and Microsoft - Ballard Power Systems (BLDP) announced that the company has launched a three-year project through a collaboration with Caterpillar (CAT) and Microsoft (MSFT) to demonstrate a power system incorporating large-format hydrogen fuel cells to produce reliable and sustainable backup power for data centers. The project is supported and partially funded by the U.S. Department of Energy, or DOE, under the H2@Scale initiative and backed by the National Renewable Energy Lab, or NREL. Ballard will provide an advanced, 1.5 MW ClearGenTM-II hydrogen fuel cell power generator.

08:45 EST Global Technologies provides update on Tersus Power's hydrogen production - Global Technologies is pleased to provide the following update on Tersus Power's hydrogen production and dispensing station. The company said, "As Tersus Power Inc. looks to roll out its first of its kind 1250Kg per day Hydrogen Production & Dispensing Station, what makes it stand above all the other hydrogen generation technologies? 1) Tersus is lowering the barrier to entry into the market by reducing the initial capital investment required to deploy a hydrogen fueling station. 2) Tersus is reducing the operational cost through intelligent engineering and design by reducing the total maintenance and feedstock requirements while greatly extending the operational life span of its modular system to over 15 years. 3) Ability to produce and dispense hydrogen onsite at a significantly lower price than any known competitor currently in the market today. 4) Onsite translates to eliminating the need and associated high expense of transporting hydrogen from offsite "refineries." 5) Utilizes "active storage" using two redundant reformation/compression systems in each Hydrogen Production & Dispensing Station. The Tersus Hydrogen Production Station looks to be a solution to the California Clean Transportation Program. Hydrogen fuel cell electric vehicles are critical to the state's goal of getting 1.5 million zero-emission vehicles on California roads by 2025. They are also a vital part of the state's work to achieve its climate change goals, improve air quality, and reduce reliance on fossil fuels. The California Energy Commission is supporting the adoption of zero-emission hydrogen fuel cell electric cars by expanding California's network of hydrogen refueling stations throughout the state. Hydrogen fuel cell electric cars have many advantages over vehicles powered by fossil fuels, including, refuel in less than five minutes at retail stations, produce water vapor, with zero tailpipe emissions and Hydrogen fuel can be sustainably produced."

08:41 EST Phunware acquires additional 398 bitcoin for $23.8M in cash - Phunware announced it has purchased an additional 398 bitcoin for approximately $23.8M in cash at an average price of approximately $59,917 per bitcoin, inclusive of fees and expenses. As of November 22, 2021, Phunware holds an aggregate of approximately 529 bitcoin, which were acquired at an aggregate purchase price of approximately $31.8M and an average purchase price of approximately $60,191 per bitcoin, inclusive of fees and expenses.

08:39 EST Point Biopharma to host virtual education event - POINT Biopharma announced that it will host a virtual education event titled "The First Principles of Radiopharmaceuticals" on Monday, December 6, 2021 at 12:00 pm ET. The event will feature a presentation and a Q&A session from the Company's executive leadership team including, Dr. Joe McCann, Chief Executive Officer and Dr. Neil Fleshner, Chief Medical Officer. This event will cover the "First Principles of Radiopharmaceuticals" to educate investors, analysts, partners, and industry stakeholders on the journey From Neutron To PatientTM. Audience members will leave with a broader understanding of how radiopharmaceuticals work, their strengths and weaknesses, considerations that impact their design, as well as how they are made.

08:39 EST RushBet partners with LaLiga in Colombia - RushBet, the sportsbook in Colombia operated by Rush Street Interactive, has teamed up with LaLiga to become the prominent Spanish soccer league's exclusive wagering partner in Colombia. The deal enables RushBet to co-brand with the two top divisions of LaLiga - LaLiga Santander and LaLiga Smartbank. RushBet may use all LaLiga IP, including team logos and jerseys, as well as have certain LaLiga players.

08:38 EST Itafos announces publication of inaugural ESG report - Itafos announced the publication of its inaugural environmental, social and governance report. The Company's inaugural ESG report describes the Company's progress on ESG matters to date and outlines the Company's directional goals moving forward. "We are pleased to publish our inaugural ESG report. Through this publication, we set a baseline for our corporate-wide ESG initiatives and establish a framework to measure our ESG goals and performance moving forward," said G. David Delaney, CEO of Itafos.

08:36 EST Achieve Life Sciences completes fifth DSMC review for Phase 3 ORCA-2 trial - Achieve Life Sciences announced the completion of the fifth and final Data Safety Monitoring Committee review for its Phase 3 ORCA-2 smoking cessation trial of cytisinicline. The DSMC concluded that there are no concerns regarding the Phase 3 study conduct and the safety and adverse event profile remains favorable. Additionally, the DSMC members commented that compliance with study medication was excellent and the study has progressed well despite the challenges of the COVID-19 pandemic. The ORCA-2 trial is designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily for either 6 or 12 weeks, compared with placebo. Subjects in the trial have completed study treatment and continue to receive standard behavioral support while completing follow-up assessments through 24 weeks post randomization. Fully enrolled this July, 810 participants were randomized across the 17 clinical sites in the United States. Preliminary data is expected in the first half of 2022. "We are grateful to the DSMC members for their diligence and guidance during these reviews and are very pleased with the outcome," commented Cindy Jacobs, President and Chief Medical Officer of Achieve. "The successful safety reviews during this ORCA-2 study are important for cytisinicline, as we believe the potential safety and tolerability of cytisinicline will be a key differentiator to existing treatments. We look forward to announcing ORCA-2 topline results in the first half of 2022."

08:35 EST Paloma Partners to acquire Goodrich Petroleum for $23.00 per share - Goodrich Petroleum announced that it has entered into a definitive merger agreement pursuant to which a subsidiary of Paloma Partners VI Holdings, an affiliate of EnCap Energy Capital Fund XI L.P., will commence a tender offer to acquire all of Goodrich's outstanding common shares for $23.00 per share in cash. The offer price in the transaction, which has been unanimously approved by Goodrich's Board of Directors, represents an approximate 7% premium to Goodrich's closing price on November 19, 2021, and a 47% premium to its year-to-date volume-weighted average price. The tender offer will be subject to customary conditions, including the tender of a majority of the outstanding Goodrich shares pursuant to the offer, and is expected to close in December 2021. The transaction is not subject to a financing condition. Paloma has secured from EnCap equity financing commitments for the entire acquisition, including assumption of debt, to complete the transaction. Upon the completion of the transaction, Goodrich will become a privately held company and shares of Goodrich common stock will no longer be listed on any public market.

08:34 EST MedMen announces Michael Serruya as Chairman and Interim CEO - MedMen Enterprises announced its Board of Directors has appointed Michael Serruya as Chairman and Interim CEO, effective immediately. Serruya succeeds outgoing Chairman and CEO Tom Lynch, who held the position since 2020 and oversaw the Company's operational turnaround. Serruya joined MedMen's board in August as part of a $100M investment in the Company by Serruya Private Equity to expand its operations in key markets and identify and accelerate further growth opportunities across the United States. This, together with Tilray, Inc.'s acquisition of the majority of the outstanding senior secured convertible notes of MedMen that were originally held by certain funds affiliated with Gotham Green Partners provides MedMen with the flexibility to execute on its growth priorities and explore additional strategic opportunities. Serruya is a seasoned cannabis investor with extensive retail expertise, having previously served as CEO of Coolbrands, Eskimo Pie Tropicana "We want to thank Tom for his leadership over the past 20 months as he's led a successful and disciplined turnaround plan, which has left us well positioned for accelerated growth as MedMen 2.0," said Serruya. "Our focus now is taking this Company to the next level as we seek to leverage the strength of the MedMen brand and consumer experience in order to expand it across the United States, Canada and internationally."

08:34 EST AMC Networks announces CFO Christina Spade to take on role of COO - AMC Network (AMCX) announced it has elevated Christina Spade, adding Chief Operating Officer, COO, responsibilities to her current role as Chief Financial Officer, CFO. In this new dual role, Spade will have operating oversight of businesses, including AMC Networks International, while continuing to lead financial operations, investor relations and global technology, for the AMC Networks portfolio of targeted streaming services and award-winning brands. Based in New York, she will continue to report to AMC Networks Interim CEO Matt Blank.

08:32 EST Safe-T launches new corporate, investor website - Safe-T Group is pleased to announce the launch of its brand new corporate and investor relations website. The new site is now officially available, and the URL is www.safetgroup.com. The new website reflects Safe-T Group's mission of becoming a leader in the privacy and cybersecurity software market for consumers and enterprises, and is aligned with its goals of generating greater investor transparency, engagement and shareholder value.

08:32 EST Perrigo to voluntary delist from Tel Aviv Stock Exchange - Perrigo Company announced that it is taking steps to voluntarily delist the Company's ordinary shares from trading on the Tel Aviv Stock Exchange, or TASE. Perrigo is delisting its shares from the TASE after divesting its Israeli-based operations earlier this year. As such, Perrigo has requested that the TASE immediately initiate the process to delist the Company's ordinary shares. Under Israeli law, the delisting of Perrigo's ordinary shares from the TASE is expected to become effective three months after the date of the Company's request to the TASE to delist the Company's ordinary shares, which occurred on November 22. Perrigo ordinary shares will continue to be listed on the NYSE, and all of its ordinary shares now traded on the TASE are expected to be transferred to the NYSE where they can continue to be traded.

08:30 EST Hamilton Thorne sees normalized sales growth in Q4 - Mr. Wolf added, "Our outlook for the balance of the year is positive with expected normalized sales growth in the fourth quarter which should continue for the foreseeable future. While supply chain issues have created new challenges, we believe that they are affecting all market participants and we have demonstrated our ability to navigate product shortages and extended lead times without a material impact on sales. We are planning across the board price increases in early 2022 that should address the margin impacts we had in Q3. We do repeat our caution that the resurgence of Covid-19 cases in certain parts of the world based on new variants and the supply chain issues we have discussed could impact on sales and profitability for a period of time that is difficult to predict."

08:26 EST Akoya Biosciences to host Spatial Day on December 15 - Akoya Biosciences announced that it will host an inaugural Spatial Day on December 15, 2021 at 12 p.m. ET. The program will feature Akoya speakers and experts at the forefront of this new field who will discuss how spatial biology is uniquely positioned to address challenges in discovery, translational and clinical research, where the field is headed, and Akoya's vision for the future. The company said, "Akoya is a pioneer in the rapidly emerging field of spatial phenotyping, a transformational new application that is giving unprecedented context to cell-cell interactions within tissue biology. Understanding spatial biomarker signatures within the framework of spatial phenotyping has the potential to unlock an explosion of new applications in medicine and research, such as the ability to segment patient populations based on immune interactions, development of spatial diagnostic assays, drug discovery, and design or identification of personalized therapeutic interventions. Biomarkers that predict response or resistance to drugs, based on understanding specific types and subtypes of immune cells and the ability to map their spatial distribution, are among the most advanced opportunities with spatial phenotyping."

08:24 EST Codex DNA, RNAimmune collaborate to optimize mRNA synthesis, delivery kits - Codex DNA and RNAimmune announced the initiation of work under a collaboration to optimize the development and validation of Codex DNA's future mRNA synthesis kits. Over the past two years, mRNA has emerged as a promising platform for the development of vaccines and therapeutics. However, robust and reliable production of mRNA remains challenging, resulting in significantly increased timelines during the critical phases of discovery and development that call for rapid iterations of construct designs for optimization. Codex DNA addresses these challenges by empowering researchers with an automated solution for their mRNA synthesis needs. Automated synthesis of mRNA from a digital sequence input reduces the build process by weeks and shrinks the iterative cycle time. RNAimmune has expertise in mRNA technology and has proprietary design, delivery, and self-amplifying platforms focused on infectious diseases, autoimmune diseases, rare disorders, and immuno-oncology. As part of this collaboration, RNAimmune scientists will use their proprietary technology to rapidly evaluate and validate Codex DNA's emerging solutions for automated synthesis and delivery of mRNA molecules with increasing complexity and functionality.

08:22 EST Sysco announces new climate goal to reduce emissions - Sysco announced it has set a climate goal to reduce emissions across its global operations and the company's entire value chain. Sysco's new science-based emissions reduction target aligns with the Paris Agreement. The company is pursuing validation of the goal by the Science-Based Targets initiative and aims to: Reduce its Scope 1 and 2 emissions by 27.5% by 2030, and Ensure that suppliers covering 67% of Sysco's Scope 3 emissions establish science-based targets by 2026. Sysco's Scope 1 and 2 reduction efforts will be achieved in part by electrifying 35% of the company's U.S. tractor fleet by 2030, equivalent to adding nearly 2,500 electric trucks to its fleet. In addition, the company will source 100% renewable electricity for its global operations by 2030. "At Sysco, we recognize and take seriously our role as a global industry leader. We understand that taking action now on climate change is important to the future of our planet and have developed an actionable, achievable plan with a clear roadmap to meaningfully reduce emissions. Over time, we believe we will be able to do more and are motivated to further our work across the value chain to quicken the pace of innovation and provide a pathway for other companies to participate in climate action," said Neil Russell, Sysco's Senior Vice President of Corporate Affairs and Chief Communications Officer, "To ensure we hold our selves accountable, our CSR strategy is now an integral part of our new business strategy, our Recipe for Growth, which is designed to advance our pace of leadership, further differentiate Sysco, create a sustainable competitive advantage and make a positive impact on the world."

08:21 EST Isos Acquisition, Bowlero announce effectiveness of registration statement - Following the release of a second consecutive quarter of results by Bowlero Corp. (BOWL), Isos Acquisition Corporation (ISOS) and Bowlero announced that Isos's registration statement on Form S-4 related to their previously announced proposed business combination has been declared effective by the U.S. Securities and Exchange Commission. The declaration of effectiveness of the Registration Statement by the SEC and the filing of the definitive proxy statement is an important step in Bowlero becoming a public traded company listed on the NYSE under the ticker symbol "BOWL" at the close of the Business Combination. Isos will hold an extraordinary general meeting of shareholders at 11:00 a.m. Eastern Time on December 14, 2021 to approve, among other things, the Business Combination with Bowlero. Shareholders of record at the close of business on November 4, 2021 will be entitled to receive notice of and to vote at the Special Meeting. The meeting will be broadcast virtually over the internet by means of a live audio webcast at https://www.cstproxy.com/isosacquisitioncorp/2021. Closing is anticipated for December 15, 2021.

08:20 EST Biocept launches single test that distinguishes between SARS-CoV-2, influenza - Biocept (BIOC) now offers a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions. This new assay expands the company's COVID-19 testing program, which began in June 2020 and has now received more than 670,000 samples for processing. Biocept's combined COVID-19 and influenza testing uses a sensitive and specific RT-PCR platform to detect and distinguish between SARS-CoV-2 and influenza. Samples are collected through nasal swab and processed through Biocept's CLIA-certified, CAP-accredited laboratory with results typically within approximately 48 hours from receipt of sample, providing timely and accurate results. While Biocept continues to expand and perform COVID-19 testing services with Thermo Fisher (TMO) diagnostic platform and kits, which are FDA approved, commercialization of the co-developed AEGEA Biotechnologies COVID-19 assay will be delayed, as a result of newly announced changes to FDA requirements for laboratory-developed COVID-19 tests.

08:19 EST Konica Minolta Healthcare Amercias launches mobile x-ray, flat panel detector - Konica Minolta Healthcare Americas announces the launch of the mKDR Xpress Mobile X-ray System and the AeroDR Carbon Flat Panel Detector, two solutions that are powerful alone yet extraordinary when used together. These new solutions reaffirm Konica Minolta's commitment to digital radiography by enabling clinicians to realize greater potential with X-ray, the most widely available diagnostic imaging modality and often the first imaging test a patient receives. Konica Minolta will introduce the mKDR Xpress Mobile X-ray System and the AeroDR Carbon Flat Panel Detector at the 2021 Annual Meeting of the Radiological Society of North America, November 28 - December 2, 2021.

08:17 EST Regencell Bioscience announces over $1M ordinary share purchase by CEO - Regencell Bioscience Holdings Limited announced that Yat-Gai Au, the Company's Chairman & CEO, made Ordinary Share purchases of Regencell totaling $1,125,807. As per the Schedule 13D filed with the SEC on November 22, Mr. Au has used an aggregate of $1,125,807 of his personal funds to purchase Ordinary Shares made through the Reporting Persons' Rule 10b-18 Plan. According to the 10b-18 Plan, following the purchases, Mr. Au owns a total of 10,392,584 Ordinary Shares, representing 80.15% of Ordinary Shares issued and outstanding. Mr. Au noted, "These share purchases using my personal funds, reflects my confidence in Regencell's business strategy of becoming a market leader for the treatment of ADHD and ASD disorders, as well as infectious diseases such as COVID-19 Our research and studies aim to address the fundamental causes of and achieve improvements in both symptoms and overall health of patients, as compared to currently available medications for ADHD/ASD disorders and COVID. We believe that we can make a difference!"

08:16 EST Sodexo partners with Simpson Senior Services Communities - Sodexo is proud to partner with Simpson Senior Services Communities to implement creative approaches to dining services that improve the dining experience, prioritize safety and foster a heightened sense of community. As the new food service partner of Simpson Senior Services Communities, Sodexo will enhance the dining experience by working hand-in-hand with residents and activities partners to incorporate both regional and international cuisines in addition to innovative food services. Residents will also have the opportunity to join a dining enhancement committee and share direct input on their preferred food dining experience.

08:15 EST Capstone Green Energy gets follow-on order for 800kW energy system in Korea - Capstone Green Energy announced that its Distributor in Korea, CY Tech, has obtained a follow-on order for a Capstone 800kW green energy system for installation at the Noksan Sewage Treatment Plant in Busan, Korea. The new installation follows the successful implementation of a 600kW energy system at the Nambu Sewage Treatment Plant, which is also located in Busan. According to the World Resource Institute, the world needs more energy to support growing populations and expanding cities. Using waste for energy is a cheap, renewable, and readily available form of energy for many cities. Since sewage treatment plants can use biogas generated from their own sludge to power their operations, it allows them to be energy self-sufficient. This ensures that a sewage plant's primary function -- removing pollutants and disease-causing pathogens -- is not interrupted by surrounding power outages.

08:14 EST Star Equity announces private placement of 650,000 shares - Star Equity Holdings announced the Company's intent to undertake a private placement of 650,000 shares of the Company's common stock to Jeffrey E. Eberwein, Executive Chairman of the Company. The proposed private placement was approved by a Special Committee made up of independent directors and the Audit Committee of the Board of Directors of the Company. The common stock will be sold at a price of $3.25 per share, representing a 25.97% premium to the Company's closing stock price on November 15, 2021, the day before the Special Committee considered and approved. The private placement is expected to close on or about December 10, 2021, subject to customary closing conditions. The Company expects to use the net proceeds from the private placement for general corporate purposes, including general business support and working capital needs.

08:12 EST Athenex to present subgroup analysis from Phase 3 study of KX-ORAX-001 - Athenex announced that an abstract for a subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar for the treatment of metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium, to be held from December 7 to December 10, 2021. The abstract and poster provide data from a post hoc, subgroup analysis of safety, progression free survival and overall survival of patients with elevated liver enzymes from study KX-ORAX-001, a Phase 3 study of weekly Oral Paclitaxel plus Encequidar vs IV Paclitaxel 175mg/m2 every three weeks. 402 subjects were randomized in a 2:1 ratio to Oral Paclitaxel and Encequidar vs IV Paclitaxel. Prior to treatment, 122 patients out of 402 total study patients had elevated AST or bilirubin, primarily mild hepatic dysfunction. For patients with elevated liver enzymes receiving Oral Paclitaxel, the median survival was 18.9 months compared to 10.1 months for patients receiving IV Paclitaxel: with a hazard ratio of 0.593 favoring Oral Paclitaxel. Although metastatic breast cancer patients with mild hepatic dysfunction at baseline are at increased risk of early serious neutropenic and infectious/septic complications this risk may be counterbalanced by a potential increase in efficacy after treatment with Oral Paclitaxel.

08:11 EST Windtree Therapeutics announces research on cardiogenic shock patients - Windtree Therapeutics announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients. U.S. hospital claims data reveals that inpatient mortality for cardiogenic shock patients was 30% in 2020. The analysis, along with previously reported primary market research with 100 U.S. cardiologists noting a high need for new therapies and their high likelihood of using an agent with istaroxime's observed clinical profile further reveals the need for improved pharmacologic innovation for cardiogenic shock patients. The average length of stay for patients with cardiogenic shock was 19.6 days with a median of 10 days in 2020. According to the Agency for Healthcare Research and Quality, the U.S. national average for a hospital stay of any disease was 4.6 days in 2020. "We are working to complete our early cardiogenic shock study with istaroxime with the ultimate goal of developing a therapy that can be used earlier to rapidly improve blood pressure and cardiac function without unwanted side effects of many existing, older agents," said Craig Fraser, CEO and President of Windtree Therapeutics. "In the next few months, we should be in a position to assess the results of this initial early cardiogenic shock study and if positive, will meet with regulatory agencies to discuss the development program and approval requirements and the potential for applying for supportive pathways that could accelerate development timelines." The istaroxime phase 2 study in early cardiogenic shock is an international, randomized, double blind, placebo- controlled study. It will include approximately 60 SCAI class B early cardiogenic shock patients with severe heart failure and systolic blood pressures between 75-90 mmHg - all will receive standard of care with 30 assigned to istaroxime and 30 assigned to placebo.

08:09 EST Helix Energy gets 5-well complete abandonment contract offshore New Zealand - Helix Energy Solutions Group has been awarded a 5-well complete abandonment project by New Zealand's Ministry of Business, Innovation & Employment, MBIE, to be performed by the Helix Q7000 and 10K Intervention Riser System, IRS. The contract with MBIE is the second recent award for Helix in the Asia Pacific region, following the award of Cooper Energy BMG wells abandonment in Australia's Bass Strait. The Q7000 is expected to mobilize late 2022 to the Tui Field, offshore New Plymouth, and perform the work in three phases, including well abandonment, recovery of XTs and wellhead severance and recovery. Excluding mobilization, the project is anticipated to last approximately 60 days. David Carr, Senior Vice President - International for Helix Well Ops, said, "This award, coming on the heels of our award with Cooper Energy, shows that an integrated vessel package such as the Q7000 can address a wide range of subsea decommissioning challenges. With Schlumberger, our partners in the Subsea Services Alliance, we provide a complete solution to complex decommissioning scopes. As we commence this project, we look forward to working with tangata whenua, MBIE and the wider community to protect and restore the mana of this location." "Helix was awarded the contract after a competitive procurement process to select a supplier that met MBIE's objectives of a robust technical solution, flexibility in timing, competitive pricing and a commitment to working with iwi and local stakeholders," said MBIE Tui Project director Lloyd Williams. "Helix is widely recognized internationally as one of the largest and most capable contractors for well intervention and abandonment, and we are looking forward to working with them to complete the final phase of the decommissioning. Helix's proposed vessel to carry out the work, the Q7000, is a state-of-the-art unit which is optimized for well decommissioning and features specialized equipment required to complete the work safely and efficiently," said Williams.

08:08 EST Oryx Gaming granted UK supplier license - Oryx Gaming, a Bragg Gaming company, has been granted a UK license, a significant milestone which will see the company enter a mature iGaming market. The supplier license, awarded by the United Kingdom Gambling Commission, or UKGC, will enable Bragg's Oryx Gaming to provide its content to operators.

08:08 EST Breeze Holdings Acquisition announces additional $1.15M added to trust account - Breeze Holdings Acquisition announced that its sponsor, Breeze Sponsor, timely deposited an aggregate of $1.15M, representing 10c per public share, into the company's trust account in order to extend the date by which the company has to consummate a business combination from November 25, 2021 to February 25, 2022. The Sponsor loaned the Extension Payment to the company in exchange for a promissory note in the amount of the Extension Payment. The loan under the promissory note is non-interest bearing and will be repaid upon the consummation of a business combination. The company's stockholders are not entitled to vote on or redeem their shares in connection with such extension.

08:07 EST Veeco ships first LSA101 Laser Spike Annealing System from San Jose facility - Veeco Instruments announced they have shipped the first LSA101 Laser Spike Annealing System from their new San Jose, California facility to a leading semiconductor manufacturer. Veeco's new, SEMI-compliant facility serves as the company's center of excellence for the development and production of laser annealing and advanced packaging lithography systems for semiconductor applications. "We are extremely proud to be shipping our first LSA system from our state-of-the-art facility in the heart of Silicon Valley," commented Bill Miller, Veeco's Chief Executive Officer. "Aligned with the company's growth strategy, this new manufacturing space enables Veeco to serve the world's leading semiconductor chip providers with increased capacity and world-class lab space. We look forward to showcasing this flagship location to our laser annealing and advanced packaging lithography customers for years to come. Thank you to the Veeco team that worked diligently on an accelerated timeline to enable this exciting milestone in Veeco's history." Veeco's new facility features approximately 70,000 square-feet of manufacturing and engineering lab space and 30,000 square-feet of office space. Manufacturing space will be nearly double that of Veeco's previous San Jose facility and will improve manufacturing efficiency. The new facility is specifically designed to meet growing demand for Veeco's laser annealing and advanced packaging lithography technologies.

08:05 EST Communications Systems to sell headquarters building for $6.8M - Communications Systems announced that it entered into a purchase agreement with Buhl Investors, a Minnesota limited liability company or its affiliated assignee for the sale of the company's headquarters building located at 10900 Red Circle Drive, Minnetonka, Minnesota for $6.8M. The building currently includes the CSI's corporate administrative offices, as well as some operations of the company's JDL Technologies and Ecessa businesses within its Services & Support operating segment. The building also supports business operations CSI is performing under the transition services agreement it entered into with Lantronix (LTRX) following the sale of its Transition Networks and Net2Edge businesses to Lantronix on August 2. The closing of the transaction is subject to a number of closing conditions, including the Buyer's ability to complete due diligence within 90 days, the buyer's ability to obtain regulatory approval for its intended use of the property as a multi-tenant office building, as well as CSI and the buyer negotiating and entering a lease agreement under which CSI would lease a portion of the space within the building. If the sale proceeds, the company currently expects the transaction to close within the first quarter of 2022.

08:03 EST Landsea Homes to build 139 new homes in Placentia - Landsea Homes announced that it plans to build 139 new homes for a new community called Hudson in Placentia in North Orange County, California. Hudson will offer 139 three-story townhomes, consisting of 63 traditional row townhomes and 76 back-to-back townhomes. The Dutch woonerf design concept embraces the idea of a "living street" between the buildings with room for pedestrians and cyclists.

08:03 EST Bionano Genomics announces publication outlining approach to OGM adoption - Bionano Genomics announced the publication of a study by Johns Hopkins University in the Journal of Clinical & Anatomic Pathology outlining a stepwise approach to adoption of OGM for cancer analysis in the cytogenetics lab. Conducted as a blinded comparison to a comprehensive collection of tools, this study compared results from OGM to those from whole-genome chromosomal microarrays from Illumina, fluorescence in-situ hybridization probes from Abbott, a targeted panel by next-generation sequencing from Illumina, a gene fusion panel by gene expression on the nCounter from NanoString and traditional g-banding by karyotyping. The cohort comprised five different cancer subjects and multiple sample types: four leukemia/lymphoma subjects and one solid tumor subject across three bone marrow samples, one peripheral blood sample and one solid tumor sample. The findings by OGM were concordant with those obtained by CMA and NGS for copy number variants and FISH and karyotyping for balanced structural variations such as inversions and translocations. Sensitivity compared to CMA was 96% excluding copy neutral loss of heterozygosity calls. Sensitivity compared to karyotyping and FISH was 100%. OGM also revealed substantially more SVs than the traditional methods, including an additional 51 CNVs and 20 SVs. Of the variants revealed by OGM that were not detected by the standard methods, 52% involved genes and 7.7% of them involved known cancer genes. The other 48% were classified as variants of unknown significance. The authors point out that these VOUSs have the potential to play a role in further refining patient diagnosis and identifying novel proteins that could be therapeutic targets. OGM was also used in the study to provide high resolution analysis of subjects with complex karyotypes exhibiting chromothripsis. Chromothripsis, or chromosome shattering, results in highly complex chromosomal structures that are typically very challenging to unravel by CMA, FISH and karyotyping. OGM provides a more comprehensive view across the genome that targeted methods like FISH cannot give and it has been shown to have a higher resolution than traditional methods as well. Compared to karyotyping, which has a resolution of 5 Mbp, OGM's resolution is 10,000 times higher and compared to CMA, OGM's resolution is 20-100 times higher, depending on the probe density used on the array. The authors used OGM to reveal and characterize chromothripsis in leukemia subjects with unprecedented scope and resolution, which they said can be extremely helpful in determining if there are druggable variants present, markers consistent with aggressive disease or disease that's treatment refractory. The principal conclusions of this publication is that OGM provides an alternative workflow that provides valuable genomic information often with higher resolution than traditional methods without sacrificing sensitivity. OGM is complementary to methods like NGS, which reveal sequence variants, and provides an opportunity to simplify and consolidate workflows for SV analysis by using OGM as an alternative to CMA, FISH and karyotyping.

08:02 EST KeyBank National Association acquires XUP Payments, terms not disclosed - KeyBank National Association announced that it has acquired XUP Payments, a B2B focused digital platform. Key will leverage this technology to enhance the experience across its commercial product set and more broadly advance Key's embedded banking strategy. The acquisition is the latest in a series of strategic fintech alliances to bring best-in-class payments and banking services to clients.

07:50 EST Astra completes first commercial orbital launch for United States Space Force - Astra successfully completed its first commercial orbital launch for the United States Space Force late Friday night, November 19. The launch, STP-27AD2, was conducted from Astra's Kodiak Spaceport, located at the Pacific Spaceport Complex in Kodiak, Alaska. Astra's launch system demonstrated the orbital placement of a test payload to an inclination of 86.0 degrees at an altitude of 500 km. The payload achieved an orbital velocity of 7.61 kilometers per second in eight minutes and 47 seconds. The United States Space Force contracted this launch through a Defense Innovation Unit Other Transaction Agreement.

07:39 EST Zai Lab appoints Richard Gaynor to board of directors - Zai Lab (ZLAB) announced that it has appointed Richard Gaynor, M.D., to its Board of Directors. Gaynor will also serve as Chair of the Research and Development Committee. Gaynor is the President and Chief of Research and Development of BioNTech (BNTX) US.

07:38 EST Provention Bio provides update on response to FDA concerning teplizumab - Provention Bio provided an update on its ongoing efforts to address FDA considerations cited in the Complete Response Letter, or CRL, issued to the Company by the FDA on July 2 pertaining to comparability between the Company's planned teplizumab commercial product and clinical drug product used in historical trials of teplizumab. On November 18 the Company had a Type A meeting with the FDA to discuss the population pharmacokinetic (popPK) model to be used for the purpose of planned commercial and clinical drug product comparison. In preliminary meeting comments, the FDA approved the Company proceeding to populate the popPK model with data collected from patients receiving therapeutic doses of teplizumab in a pharmacokinetic/pharmacodynamic, or PK/PD, substudy of the ongoing PROTECT Phase 3 trial in newly diagnosed type 1 diabetes, or T1D, patients.

07:36 EST Pipestone Energy announces normal course issuer bid - Pipestone Energy announced the Toronto Stock Exchange has accepted the notice filed by the Company to implement a normal course issuer bid. The NCIB allows Pipestone to purchase up to 9,598,347 common shares, representing 5% of its 191,966,942 outstanding Common Shares as at November 12, 2021. The NCIB is scheduled to commence on November 25, 2021 and is due to expire no later than November 24, 2022. Under the NCIB, Common Shares may be repurchased in open market transactions on the TSX and other alternative trading platforms in Canada and in accordance with the rules of the TSX governing NCIB's. The total number of Common Shares Pipestone is permitted to purchase is subject to a daily purchase limit of 55,099 Common Shares, representing 25% of the average trading volume of 220,397 Common Shares on the TSX calculated for the six-month period ended October 31, 2021; however, Pipestone may make one block purchase per calendar week which exceeds the daily repurchase restrictions. Any Common Shares that are purchased under the NCIB will be cancelled upon their purchase by the Company. Pipestone intends to fund the purchases out of its available resources and is implementing the NCIB as part of its free cash flow allocation strategy. Pipestone believes that, at times, the prevailing share price may not reflect the underlying value of the Common Shares and the repurchase of Common Shares represents an opportunity to improve per share metrics as part of the Company's commitment to shareholder returns. The Company plans on repurchasing Common Shares under the NCIB following its commencement date. The Company intends to enter into an automatic securities purchase plan effective November 25, 2021, under which its broker may purchase Common Shares in connection with the NCIB. The plan will contain a prearranged set of criteria in accordance with which its broker may make Common Share purchases. These strict parameters enable the purchase of Common Shares during times when it would ordinarily not be permitted due to self-imposed blackout periods, insider trading rules or otherwise. Such plan is adopted in accordance with applicable Canadian securities laws. Outside of blackout periods, Common Shares may be purchased under the NCIB in accordance with management's discretion.

07:35 EST Golden Star Resources receives regulatory approval for Chifeng acquisition - Golden Star Resources announced that the Ghanaian Ministry of Lands and Natural Resources has informed Chifeng Jilong Gold Mining that it has no objection to Chifeng becoming the controller of Golden Star, via Chifeng's subsidiary, Chijin International and/or its assignee. GSWL is Golden Star's 90% owned subsidiary that holds the mineral rights relating to the Wassa gold mine. The no objection letter was issued in accordance with section 52 of the Minerals and Mining Act, 2006 and on the advice and recommendation of the Minerals Commission. The Ministry's approval of the transaction is subject to customary conditions. Golden Star, Chifeng and the Purchaser entered into a definitive agreement dated October 31. Pursuant to and upon completion of the Transaction, holders of Golden Star Shares will receive total consideration, payable in cash, of $3.91 per Golden Star Share, which equates to a total Transaction value of approximately $470M on a fully-diluted, in-the-money basis. Golden Star has engaged Canaccord Genuity as its exclusive financial advisor as well as Fasken Martineau DuMoulin and Davis Graham & Stubbs as its respective Canadian and U.S. legal advisors.

07:34 EST Novocure says last patient enrolled in Lunar trial of TTFields in NSCLC - Novocure announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fiel, TTFields, together with immune checkpoint inhibitors or docetaxel for treatment of patients with advanced stage 4, non-small cell lung cancer NSCLC following progression while on or after platinum-based therapy. Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally. "LUNAR marks Novocure's second phase 3 pivotal study to complete enrollment this quarter and is our first of several late-stage clinical trials expected to deliver final data over the next two years," said William Doyle, Novocure's Executive Chairman. "LUNAR will provide the first randomized dataset to evaluate increased survival when Tumor Treating Fields is used together with immunotherapy, versus immunotherapy alone. I am proud of our employees and am grateful to our principal investigators and patients for their courage and dedication to advancing clinical studies." LUNAR is a phase 3 pivotal trial testing the effectiveness of TTFields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage 4 NSCLC who progressed during or after platinum-based therapy. It is estimated that approximately 46,000 patients receive second-line treatment for stage 4 NSCLC each year in the U.S. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. TTFields therapy is intended principally for use in combination with other standard-of-care treatments, and LUNAR was designed to generate data that contemplates multiple outcomes. Patients will be followed for 12 months with final data expected year-end 2022.

07:33 EST Decibel Therapeutics announces Regeneron extended research term - Decibel Therapeutics (DBTX) announced that Regeneron (REGN) has extended the research term of its collaboration with the Company to discover and develop gene therapies for hearing loss. The research term will be extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10M in Q4 of 2022. Under the collaboration launched in 2017, Decibel is developing three gene therapy programs targeting congenital, monogenic hearing loss with Regeneron. Decibel plans to initiate in 2022 a Phase 1/2 clinical trial of DB-OTO, the Company's lead gene therapy product candidate, designed to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. Decibel is also advancing AAV.103 and AAV.104, gene therapy programs targeting other monogenic forms of hearing loss, with Regeneron. AAV.103 aims to restore hearing in individuals with mutations in the GJB2 gene, and AAV.104 aims to restore hearing in individuals with mutations in the STRC gene. "Decibel and Regeneron scientists have worked closely to advance our gene therapy pipeline for the treatment of congenital, monogenic hearing loss, bringing our lead program, DB-OTO, within sight of the clinic. We are pleased that Regeneron has elected to extend the research term, which extends our access to Regeneron's world-leading genomic and genetic technologies, and therapeutic discovery and development expertise," said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. "This collaboration, which plays to each party's strengths, is an important part of our ability to accelerate the discovery and development of innovative genetic therapies for patients in need." Through the collaboration, Regeneron provides Decibel with broad access to its proprietary suite of technologies to support Decibel's goal of discovering new medicines for congenital, monogenic hearing loss. Decibel retains worldwide development and commercialization rights to the product candidates being developed in the collaboration and will pay Regeneron tiered royalties based on net sales.

07:31 EST Pembina Pipeline CEO Mick Dilger steps down, Scott Burrows named interim CEO - Pembina Pipeline announced that Mick Dilger has stepped down as President and CEO to pursue other opportunities. The Board of Directors has named Scott Burrows, Pembina's current CFO, as interim President and CEO. The Board will be working with a leading search firm to identify and evaluate internal and external candidates for a new CEO to lead Pembina in its next chapter. With Burrows' appointment, Cameron Goldade, currently Pembina's Vice President - Capital Markets, has been appointed interim CFO.

07:28 EST Myriad Genetics to present new data at SABCS - Myriad Genetics announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium, SABCS, that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment. Genomic Instability Scores to Guide Eligibility for Treatment with PARP Inhibitors. Poster Title: "Identifying homologous recombination deficiency in breast cancer: genomic instability score thresholds differ in breast cancer subtypes." This study, with collaboration from researchers at Mayo Clinic and Johns Hopkins, assesses the differences in genomic instability score thresholds for different types of breast cancer using the GIS for ovarian cancer as a comparator to guide the identification of potential candidates for treatment with PARP inhibitors.Finding Ways to Improve Polygenic Risk Scores by Reducing Ancestral Bias. Poster Title: "Integration of an ancestry-inclusive polygenic risk score with the Tyrer-Cuzick breast cancer risk model." This study, done in collaboration with researchers from Cleveland Clinic, University of Pennsylvania, and Dana-Farber Cancer Institute, validates the integration of an ancestry-inclusive breast cancer polygenic risk score with a clinical and family history-based model in the development of a risk assessment tool that is both genomically-informed and equitable.

07:25 EST Ayr Wellness to acquire Gentle Ventures for upfront payment of $55M - Ayr Wellness has entered into an agreement to acquire Gentle Ventures, LLC d/b/a Dispensary 33, and certain of its affiliates that collectively own and operate two licensed retail dispensaries in Chicago, Illinois. Dispensary 33 operates two locations in Chicago, one on the lively N Clark Street in the Andersonville neighborhood, and the other on W Randolph Street in West Loop, a former industrial meatpacking district that has become one of Chicago's most popular neighborhoods for restaurants, nightlife and hospitality. Ayr intends to acquire the equity interests in Dispensary 33 pursuant to a definitive purchase and sale agreement proposed to be entered into between Ayr, its affiliate, and Dispensary 33 and the holders of 100% of the equity interests' holders of Dispensary 33. Purchase consideration is expected to consist of $55M upfront, including $12M of cash, $3M of sellers notes and $40M of stock. An earn-out is payable if certain Adjusted EBITDA performance is achieved through Q3 2022. The acquisition is subject to customary closing conditions and regulatory approvals, as well as the execution of the Purchase Agreement.

07:23 EST BioCryst adds $350M in financing with Royalty Pharma, OMERS Capital Markets - BioCryst Pharmaceuticals 9BCRX), Royalty Pharma (RPRX) and OMERS Capital Markets, announced transactions totaling $350M in new funding for BioCryst, with all funds immediately available at closing. The funds from these transactions will enable further advancement of BCX9930, BioCryst's oral Factor D inhibitor, toward filing for registration, expand the development of BCX9930 across multiple indications and support additional investment in the global launch of ORLADEYO. For a $150M upfront cash payment, Royalty Pharma, the largest buyer of pharmaceutical royalties globally, has purchased royalties on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor of 3.0% on sales up to $1.5B, 2.0% on sales between $1.5B and $3B, and no royalty on sales over $3B. Royalty Pharma also purchased royalties of 0.75% on direct annual net sales of ORLADEYO up to $350M, 1.75% on sales between $350M and $550M, no royalty on sales over $550M, and a tiered, declining percentage on ORLADEYO sublicense revenue in certain territories. These royalties are additional to the royalties purchased by Royalty Pharma in December 2020. For a $150M upfront cash payment, OMERS, one of Canada's largest defined benefit pension plans, has purchased a capped, tiered, declining royalty on direct annual net sales of ORLADEYO. Under the agreement, BioCryst does not owe any royalties for the first two years. The first royalty payment from BioCryst to OMERS will occur based on royalties from direct annual net sales of ORLADEYO in the fourth quarter of 2023. Once OMERS has achieved its maximum allowed total return under the agreement, no further royalty payments will be owed. OMERS will receive a royalty of at least 7.5% on annual net sales up to $350 million, 6.0% on sales between $350M and $550M and no royalty on sales over $550M. The maximum total return OMERS may earn under the agreement is capped at 1.425x or 1.550x, based on the level of 2023 global net sales of ORLADEYO relative to a prespecified sales threshold. Royalty Pharma also has extended its relationship with BioCryst through a $50M equity investment at a price of $13.00 per share, the volume-weighted average price of BioCryst common stock over the past 20 days. BioCryst also is pleased to continue its strong partnership with Athyrium Capital Management. Having now achieved the defined ORLADEYO revenue milestones in its prior agreement with Athyrium, BioCryst has committed to access the additional $75M available under the agreement and will draw this $75 million in mid-2022. The new financing enables BioCryst to further advance and expand its Factor D program over the next two years by achieving the following: Complete and report data from the ongoing REDEEM-1 and REDEEM-2 pivotal trials in PNH; Complete the renal proof-of-concept basket trial in three nephritis indications and advance to pivotal trials in each; Commence PoC trials in other complement-mediated diseases; Prepare to submit regulatory approval filings in PNH.

07:18 EST Day One announces first patient dosed in Phase 2 study of DAY101 - Day One Biopharmaceuticals announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DAY101 as a monotherapy in patients with RAF-altered solid tumors. DAY101 is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. "DAY101 has demonstrated encouraging anti-tumor activity as a monotherapy in patient populations where MAPK pathway alterations are believed to play an important role in driving disease progression," said Samuel Blackman, M.D., Ph.D., co-founder and chief medical officer of Day One. "Expanding the development of DAY101 beyond pediatric low-grade glioma represents an important step in our overall development strategy for this promising program, and we look forward to enrolling additional RAF-altered solid tumor patients in this Phase 2 monotherapy study." The multi-center, open-label umbrella study, FIRELIGHT-1, will evaluate the safety and efficacy of DAY101 in patients with recurrent or progressive solid tumors with activating RAF alterations. Day One expects to initiate a Phase 1b combination portion of the study with the Company's oral MEK inhibitor, pimasertib, in the first quarter of 2022. Day One also continues to enroll patients in a pivotal Phase 2 clinical trial of DAY101 in pediatric, adolescent and young adults with recurrent or progressive low-grade glioma harboring a known BRAF alteration (NCT04775485), with initial data expected in the first half of 2022.

07:15 EST Royalty Pharma acquires additional royalty interest in BCX9930, ORLADEYO - Royalty Pharma (RPRX), BioCryst Pharmaceuticals (BCRX) and OMERS Capital Markets announced transactions totaling $350M in new funding for BioCryst, with all funds immediately available at closing. The funds from these transactions will enable further advancement of BCX9930, BioCryst's oral Factor D inhibitor, toward filing for registration, expand the development of BCX9930 across multiple indications and support additional investment in the global launch of ORLADEYO, which is on a trajectory to become the market-leading prophylactic hereditary angioedema, HAE, therapy. For a $150M upfront cash payment, Royalty Pharma has purchased royalties on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor of 3.0% on sales up to $1.5B, 2.0% on sales between $1.5B and $3.0B, and no royalty on sales over $3.0B. Royalty Pharma also purchased royalties of 0.75% on direct annual net sales of ORLADEYO up to $350M, 1.75% on sales between $350M and $550M, no royalty on sales over $550M, and a tiered, declining percentage on ORLADEYO sublicense revenue in certain territories. These royalties are additional to the royalties purchased by Royalty Pharma in December 2020. For a $150M upfront cash payment, OMERS has purchased a capped, tiered, declining royalty on direct annual net sales of ORLADEYO. Under the agreement, BioCryst does not owe any royalties for the first two years. The first royalty payment from BioCryst to OMERS will occur based on royalties from direct annual net sales of ORLADEYO in the fourth quarter of 2023. Once OMERS has achieved its maximum allowed total return under the agreement, no further royalty payments will be owed. OMERS will receive a royalty of at least 7.5% on annual net sales up to $350M, 6.0% on sales between $350M and $550M and no royalty on sales over $550M. The maximum total return OMERS may earn under the agreement is capped at 1.425x or 1.550x, based on the level of 2023 global net sales of ORLADEYO relative to a prespecified sales threshold. Royalty Pharma also has extended its relationship with BioCryst through a $50M equity investment at a price of $13.00 per share, the volume-weighted average price of BioCryst common stock over the past 20 days. "We are excited to expand our partnership with BioCryst to continue to support their growth journey," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Following our initial investment nearly one year ago, ORLADEYO has proven to be a transformative therapy for HAE patients. We are also thrilled to make an additional investment in BCX9930 following strong proof of concept data, which will support and expand the rapid development of BCX9930 in paroxysmal nocturnal hemoglobinuria and multiple other complement-mediated diseases. Our equity investment underpins our conviction in the BioCryst team and the substantial patient need for innovative oral therapies in rare disease," Legorreta added. BioCryst also continues its partnership with Athyrium Capital Management. Having now achieved the defined ORLADEYO revenue milestones in its prior agreement with Athyrium, BioCryst has committed to access the additional $75M available under the agreement and will draw this $75M in mid-2022.

07:09 EST BeiGene begins 1st in-human Phase 1 trial of TYK2 inhibitor BGB-23339 - BeiGene announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 TYK2 inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psoriasis and inflammatory bowel disease. BGB-23339 is a potent, highly selective, investigational TYK2 inhibitor targeting the regulatory pseudokinase JH2 domain. "Discovered and developed by BeiGene, BGB-23339 is a highly selective, potent, allosteric TYK2 inhibitor that has shown promising activity in preclinical evaluation," commented Lai Wang, Ph.D., Global Head of R&D at BeiGene. "Building on our proven track record in oncology, BeiGene is expanding its clinical focus to discover new modalities and platforms in areas of high unmet need, including inflammation and immunology, to bring innovative, impactful medicines to patients." The first-in-human Phase 1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of BGB-23339. The trial is expected to enroll up to 115 healthy volunteers in Australia and/or China. In addition to its broad portfolio focused on hematological malignancies and solid tumors, BeiGene is applying its research excellence and clinical expertise to address inflammation and immunology, an area of high unmet medical need. BeiGene's internally developed, highly selective next-generation BTK inhibitor BRUKINSA is currently being evaluated in a Phase 2 trial in patients with active proliferative lupus nephritis. About BGB-23339 .

07:09 EST Kamada acquires portfolio of plasma-derived hyperimmune commercial products - Kamada announced that it has acquired a portfolio of four U.S. Food and Drug Administration-approved plasma-derived hyperimmune commercial products from Saol Therapeutics.. The combined annual global revenue of the acquired portfolio in 2021 is expected to be between $40 million to $45 million, with approximately 75% and 20% of sales generated in the U.S. and Canada, respectively. The acquired products' expected 2021 gross margins are between 50%-55%. The four acquired products include: CYTOGAM product indicated for the prophylaxis of cytomegalovirus disease associated with the transplantation of the kidney, lung, liver, pancreas, and heart. The product is the sole FDA-approved immunoglobulin product for this indication. Kamada's 2019 announced Contract Manufacturing Agreement was related to Cytogam. The tech transfer process for Cytogam is already well underway, and Kamada expects to receive FDA approval for manufacturing of the product and initiate commercial manufacturing of the product at its facility in Israel, by the end of 2022. WINRHO SDF is a Rho Immune Globulin Intravenous product indicated for use in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomies, for Rho-positive children with chronic or acute immune thrombocytopenia, adults with chronic ITP, and children and adults with ITP secondary to HIV infection. WinRho SDF is also used for suppression of Rhesus Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho-negative women. The product is FDA-approved. HEPAGAM B is a hepatitis B Immune Globulin product indicated to both prevent hepatitis B virus recurrence following liver transplantation in hepatitis B surface antigen positive patients and provide post-exposure prophylaxis. The product is FDA-approved. VARIZIG is a product that contains antibodies specific for the Varicella zoster virus, and it is indicated for post-exposure prophylaxis of varicella in high-risk patient groups, including immunocompromised children, newborns, and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients. The U.S. Centers for Disease Control recommends VARIZIG for postexposure prophylaxis of varicella for persons at high-risk for severe disease who lack evidence of immunity to varicella. The product is the sole FDA-approved IgG product for this indication. Kamada's wholly-owned U.S. subsidiary, Kamada Inc., will be responsible for the commercialization of the products in the U.S., including direct sales to wholesalers and local distributers. Under the terms of the agreement, Kamada will pay Saol a $95 million upfront payment, and up to an additional $50 million in sales milestones during 2022-2034. In addition, Kamada will acquire from Saol existing inventory at an estimated value of approximately $15 million, which will be paid over 10 equal quarterly instalments. To partially fund the acquisition costs, Kamada has secured a $40 million credit facility from Bank Hapoalim, Israel's leading commercial bank. The credit facility is comprised of a $20 million 5-year term loan and a $20 million short-term revolving credit facility. During the nine months period ending on September 30, 2021, Kamada incurred approximately $0.6 million in legal and other related fees associated with completing this transaction.

07:06 EST Local Bounti to begin trading on NYSE on November 22 - Local Bounti (LOCL) announced the successful closing of its approximately $1.1B business combination with Leo Holdings III Corp (LIII) on November 19. As a result of the closing of the business combination, Leo was renamed Local Bounti. The common stock and public warrants of Local Bounti will begin trading on the New York Stock Exchange on November 22 under the ticker symbols "LOCL" and "LOCL WS," respectively.

07:03 EST LiveOne acquires Palm Beach Records - LiveOne announced that it has completed the acquisition of Palm Beach Records. As part of the deal, LiveOne also plans to expand the studio's music operations and launch a full-service podcast recording studio. LiveOne will use the studio to break and sign new music and podcast talent, broaden its publishing, management and recording divisions, offer exclusive content to drive new LiveOne members and use the studio for franchises and South Florida-based events - where it continues to bolster its operations and events. Palm Beach Records will operate as a stand-alone wholly-owned subsidiary of LiveOne. The acquisition is to be immediately accretive to LiveOne's earnings and strengthen LiveOne's balance sheet.

07:02 EST Baidu enters license agreement with Sanofi - Baidu (BIDU) and Sanofi (SNY) have entered into an agreement to integrate Baidu's messenger ribonucleic acid design optimization platform, LinearDesign, into Sanofi's product design pipeline. Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses. This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond Covid-19.

07:00 EST MediciNova announces new data from MN-166 study - MediciNova and the JASDAQ Market of the Tokyo Stock Exchange, announced that MediciNova's research collaborator, Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, presented new data regarding MN-166, or ibudilast, from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology, or SNO, held November 18 - 21 in Boston. This study was a collaborative effort between MediciNova and Dr. Lathia and Dr. Michael Vogelbaum, Professor of Neurosurgery, Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center. Lathia presented efficacy data with MN-166 and PD-1 inhibitor combination therapy in GBM pre-clinical models. Models with GBM orthotopic tumors were treated with a PD-1 antibody alone and in combination with MN-166.

06:49 EST Pfizer, BioNTech announces follow-up data of COVID-19 vaccine in adolescents - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies' pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no serious safety concerns observed in individuals with at least 6 months of safety follow-up after the second dose. These longer-term follow-up data will form the basis for a planned supplemental Biologics License Application to be submitted to the FDA to expand approval of the vaccine for use in individuals 12 years and older. The vaccine is currently available for individuals 12 to 15 years of age under Emergency Use Authorization, granted by the FDA in May 2021. The companies also plan to submit these data to pursue regulatory approvals for this age group in other countries where emergency use authorizations or equivalents were initially granted. The updated analysis of the Phase 3 clinical trial in individuals ages 12 to 15 years was conducted in accordance with guidance from the FDA for all companies investigating COVID-19 vaccines to review safety and efficacy at key milestones. Data through up to six months after the primary vaccination series are required for licensure. These data were collected from November 2020 to September 2021. Results from this analysis of 2,228 trial participants build upon and confirm previously released data and demonstrate strong protection against COVID-19. From the 30 confirmed symptomatic cases of COVID-19 in the trial with and without evidence of prior infection with SARS-CoV-2, 30 cases of COVID-19 were in the placebo group and 0 cases were in the Pfizer-BioNTech vaccine group, corresponding to vaccine efficacy of 100%. Efficacy was consistently high across gender, race and ethnicity demographics, obesity and comorbidity status. Pfizer and BioNTech plan to submit these data for scientific peer review for potential publication. The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech's proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

06:47 EST Merck completes acquisition of Acceleron - Merck (MRK) announced the successful completion of the acquisition of Acceleron Pharma (XLRN). "This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy," said Rob Davis, CEO and president, Merck. "Fueled by Acceleron's groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need."

06:34 EST Bluebird Bio: FDA accepts BLA for betibeglogene autotemcel for priority review - Bluebird bio announced that the U.S. FDA has accepted the Biologics License Application for betibeglogene autotemcel for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with beta-thalassemia across all genotypes who require regular red blood cell transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease for patients living with beta-thalassemia in the U.S.-offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has set a Prescription Drug User Fee Act goal date of May 20, 2022.

06:12 EST High Tide to acquire 80% of NuLeaf Naturals for $31.24M - High Tide announced that it is entering into a definitive agreement pursuant to which High Tide will acquire 80% of NuLeaf Naturals for $31.24M, and will have a three-year option to acquire the remaining 20% of NuLeaf at any time. Founded in 2014 with its headquarters in Denver, Colorado, NuLeaf is a producer and distributor of cannabidiol, or CBD, wellness products. NuLeaf has a distribution reach in the natural products channel and recently secured an expansion with Sprouts Farmers Market from 33 retail locations to an additional 235 stores. Over the 12 months ended September 30, NuLeaf had over 5.1M site visits and an average order value of $120. Since its inception, NuLeaf has served approximately 330,000 unique customers through its e-commerce platform, and hundreds of thousands more through their other distribution channels. NuLeaf generated gross margins of 71% and adjusted EBITDA margins of 25% during the 12 months ended September 30, both of which are accretive to High Tide's consolidated margin profile. The transaction, which is an arm's length transaction, is subject to, among other things, receipt of required TSX Venture Exchange approval, and other customary conditions of closing, is expected to close in the coming weeks, implies an enterprise valuation of $39.05M, representing 7.1 projected 2021 adjusted EBITDA and recognition for $1.7M recently spent on upgrading NuLeaf's cGMP-certified facility. The consideration for the 80% acquired will be $31.24M in common shares of High Tide on the basis of a deemed price per High Tide Share equal to the volume weighted average price per High Tide Share on Nasdaq for the 10 consecutive trading days preceding closing of the transaction. Upon closing, NuLeaf Naturals will have approximately $500,000 of cash and inventory of approximately $500,000. In addition to the foregoing, NuLeaf's owners have agreed to grant High Tide an option to acquire all the remaining interests in NuLeaf not held by High Tide, and become the sole owner of NuLeaf, at an enterprise value equal to the trailing twelve months of adjusted EBITDA multiplied by 7.1. The call option will be exercisable at any time for a period of three years following the closing. In addition, High Tide has agreed to grant NuLeaf's owners an option to put to High Tide the remaining interests in NuLeaf not held by High Tide, at the same enterprise value of the call option. The put option will be exercisable by NuLeaf's owners for a period of 18 months following the 18 month anniversary of the closing. The consideration under the call option or the put option, if exercised, will be satisfied in cash. The High Tide Shares issued pursuant to the consideration are subject to a statutory hold period of four months and one day.

06:05 EST High Tide to acquire 80% of NuLeaf Naturals for $31.24M - High Tide is pleased to announce that it is taking another step towards solidifying itself as a major player within the global marketplace for hemp-derived CBD products, by entering into a definitive agreement pursuant to which High Tide will acquire 80% of NuLeaf Naturals for $31.24M, and will have a three-year option to acquire the remaining 20% of NuLeaf at any time. The Transaction, which is an arm's length transaction, is subject to, among other things, receipt of required TSX Venture Exchange approval, and other customary conditions of closing, is expected to close in the coming weeks, implies an enterprise valuation of $39.05M, representing 7.1 projected 2021 Adjusted EBITDA and recognition for $1.7M recently spent on upgrading NuLeaf's cGMP-certified facility. The consideration for the 80% acquired will be $31.24M in common shares of High Tide on the basis of a deemed price per High Tide Share equal to the volume weighted average price per High Tide Share on Nasdaq for the 10 consecutive trading days preceding closing of the Transaction. Upon closing, NuLeaf Naturals will have approximately $500,000 of cash and inventory of approximately $500,000.

06:04 EST Victory Capital stockholders approve elimination of dual-class share structure - Victory Capital Holdings announced that its stockholders approved the Company's previously announced proposal to eliminate the Company's dual-class share structure at a Special Meeting of Stockholders held on November 19. As a result of the stockholders' vote, upon the filing with the Secretary of State of Delaware of Victory Capital's amended and restated charter, Victory Capital's Class B common stock will convert into Class A common stock on a one-for-one basis, and the Company will have a single class of common stock. As a result, all holders of the Company's common stock will have identical economic and voting rights. Approximately 90% of the votes eligible to be cast at the Special Meeting of Stockholders were present either in-person or by proxy, and 99.99% of the votes cast were cast in favor of the Proposal. All stock certificates for Class A common stock or Class B common stock will automatically represent shares of Victory Capital's common stock and continue to trade under the ticker symbol "VCTR". No further stockholder action is required.

06:02 EST Mannatech declares special cash dividend - Mannatech announced that its Board of Directors declared a cash dividend of $1.70 per share of common stock, payable on Wednesday, December 29, to shareholders of record at the close of business on Wednesday, December 15. This dividend combines the quarterly dividend amount of 20c per share with a special dividend amount of $1.50 per share and demonstrates the Company's commitment to rewarding shareholders and encouraging long-term investment in Mannatech's common stock.

05:36 EST Amazon Web Services selected by adidas AG as preferred cloud provider - Amazon Web Services, or AWS, an Amazon company, announced that adidas AG has selected AWS as its preferred cloud provider for SAP workloads. With this announcement, adidas will migrate its SAP environment to AWS and implement a modern SAP S/4HANA platform. Running these business-critical SAP workloads in the cloud will enable adidas to digitize core business processes across its value chain to provide better consumer experiences, become a more data-driven business, and support new business models such as direct-to-consumer.

05:29 EST Amryt Pharma announces intention to delist from AIM - Amryt Pharma announced its intention to cancel the admission of its ordinary shares to trading on AIM with effect from 7:00 a.m. on January 11. The company's last day of trading on AIM will be January 10. Amryt will retain its listing on Nasdaq, each representing five ordinary shares, under its existing ticker symbol.

05:22 EST The9 NFT platform announces exclusive license agreement with Neymar - The9 announced that its NFT community and trading platform NFTStar has signed an exclusive license agreement with Neymar da Silva Santos Junior, a soccer player. NFTStar will develop, sell, and trade NFT collectibles authorized by NR Sports, a company specialized in image management, exclusively acting in Neymar Jr.'s career..

05:21 EST Amazon announces deals for Cyber Monday weekend - Amazon revealed a sneak peek of the thousands of deals customers can shop during its Cyber Monday deals weekend, which kicks off on Saturday, November 27, and runs through Monday, November 29. All weekend long, customers can also shop thousands of deals from independent selling partners, most of which are small and medium-sized businesses. Recently, Amazon announced plans to add 125,000 full- and part-time roles, plus an additional 150,000 seasonal jobs.

04:36 EST Zymergen CEO Flatley buys 100,000 shares for $1M - Zymergen CEO Jay Flatley disclosed the purchase of 100,000 shares for $1M. The CEO bought the shares on November 17 at a price of $10. Flatley now owns 144,789 shares of Zymergen.